Comparing Ibrance vs Tykerb
Ibrance | Tykerb |
|
---|
Ibrance (palbociclib) | Tykerb (lapatinib) |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Ibrance is a CDK4/6 inhibitor that may be used to treat advanced or metastatic hormone-receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer in combination... View more |
Prescription only
Tykerb (lapatinib) is an oral dual kinase inhibitor that is usually used in combination with other medicines to treat HER-2 positive breast cancer in postmenopausal women or HER-2 positive breast... View more |
Related suggestions Breast Cancer
|
|||||||||||||||
More about Ibrance (palbociclib) | More about Tykerb (lapatinib) | ||||||||||||||||
Ratings & Reviews | |||||||||||||||||
Ibrance has an average rating of 6.7 out of 10 from a total of 82 ratings on Drugs.com. 62% of reviewers reported a positive effect, while 30% reported a negative effect. |
Be the first to share your experience with this drug. |
||||||||||||||||
Drug Class | |||||||||||||||||
Side Effects | |||||||||||||||||
See also: Ibrance side effects in more detail. |
See also: Tykerb side effects in more detail. |
||||||||||||||||
Generic Availability | |||||||||||||||||
Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Ibrance prices |
View all Tykerb prices |
||||||||||||||||
Dosage Form(s) Available | |||||||||||||||||
|
|
||||||||||||||||
Brand Names | |||||||||||||||||
N/A |
N/A |
||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | |||||||||||||||||
29 hours |
24 hours |
||||||||||||||||
CSA Schedule ** View glossary of terms | |||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | |||||||||||||||||
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||
Drug Interactions | |||||||||||||||||
A total of 455 drugs are known to interact with Ibrance:
|
A total of 613 drugs are known to interact with Tykerb:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
|
||||||||||||||||
Disease Interactions | |||||||||||||||||
First Approval Date | |||||||||||||||||
February 03, 2015 |
March 13, 2007 |
||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | |||||||||||||||||
N/A |
N/A |
||||||||||||||||
More Information | |||||||||||||||||
Patient resources | |||||||||||||||||
Professional Resources | |||||||||||||||||
Related Treatment Guide | |||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.